#Sam Chun Dang Pharm 000250 | Stock channels

Sam Chun Dang Pharm000250

₩212,500-12.73%Close Oct 12

This is the start of #Sam Chun Dang Pharm

Talk about Sam Chun Dang Pharm here. Pull up price, chart, news and filings just for you from the message box, or mention @InverseOneBot to get an answer everyone can see.

InverseOne BotBOTOnly visible to you

Welcome to the Sam Chun Dang Pharm channel. Here's the latest data.

삼천당제약 000250

Close as of Oct 12

₩212,500-12.73%

Low ₩120,00052-week rangeHigh ₩1,233,000

At a glance: 8% of the 52-week range, estimated net outflow, lending balance growing, filing check: Quiet.

Disappears when you reload.

삼천당제약 000250

Close as of Oct 12

₩212,500-12.73%

Low ₩120,00052-week rangeHigh ₩1,233,000

5 sessions

+6.6%

20 sessions

+30.4%

60 sessions

+6.5%

Volume

1.8x average

Price

Mar 31 ~ Oct 12

₩212,500-74.37%

Low ₩126,500High ₩829,000

Money flow

as of Oct 12

Strong outflow index-₩7.3B

Net flow, Outflow

Market flow rank: Outflow #9 of 52
Sector flow rank: #13 of 13

Today's overlaps

Loan balance building + outflow index

Multi-day trend, Reversal down

Cumulative flow: +₩24.4B
outflow: 1d streak

Estimated from public price, change and volume. Not actual investor net buying.

as of Oct 12

Market cap

₩5T

Lending balance

Building

1,624,272 sh

KRW 0.35T

1D +3.64%5D +17.82%

New 97,658 sh, Returned 40,648 sh

Shares borrowed through securities lending that have not yet been returned. Borrowed shares are often sold afterwards, so the balance is used as a reference for pending sell pressure.

As of 2026-10-12, FSC stock lending data

Filing check

Quiet0 to check first, 0 improvementschecked through Oct 14

This only counts facts confirmed in filings. It does not look at whether the price is cheap or expensive, and it is not a reason to buy or sell on its own.

Earnings quality

We read the latest periodic report and check whether profit matches cash, sales match receivables, and profit from the core business matches profit from elsewhere. There is no score, only the numbers that diverge beyond a threshold and why they matter.

2026 first half, consolidated statements, filed 2026-10-08

2 numbers diverge beyond the threshold

Net profit and operating cash flow
Check this
Net profit 131억 원, operating cash flow 23억 원, 18% of net profit
Cash from operations came in well below net profit. Profit can be booked before the money arrives. Check whether receivables, inventory or contract assets grew as well.
Sales and receivables
Check this
Year on year, sales +26.1%, receivables +64.5%
Receivables 655억 원, a year earlier 398억 원
Receivables grew 38.4pp faster than sales. Collecting payment may be taking longer than before.
Sales and inventory
Year on year, sales +26.1%, inventory +24.0%
Inventory 580억 원, a year earlier 468억 원
Profit from outside the core business
Pretax profit 170억 원, operating profit 89억 원, non-operating result 81억 원
48% of pretax profit came from outside the core business.

Source filing: 2026 first half Report a year earlier

This only checks whether the statement numbers agree with each other. It ignores the share price and is not a reason to buy or sell on its own. See the formula

Sector moves

Of 13 covered Healthcare stocks in Korean, 12 fell; the average change was -3.35%. Sam Chun Dang Pharm moved in the same direction at -12.73%. Estimated sector flow was outflow.

Variables to watch Drug approvals and trial results, Drug pricing policy, US interest rates, USD/KRW

Risks to check A reversal after a -12.73% one-day swing, -83% below the high, the downtrend may continue, Clinical trial failure

Same-sector channels

Latest news

Stock page

Posts are members' opinions. Investment decisions and their consequences are your own.

Data: KRX daily bars, InverseOne quote snapshots, public news feeds, DART filings, InverseOne company research. Not a call to buy or sell.